Transcriptional Activation of MYC-Induced Genes by GCN5 Promotes B-cell Lymphomagenesis

Aimee T. Farria,Joshua B. Plummer,Andrew P. Salinger,Jianjun Shen,Kevin Lin,Yue Lu,Kevin M. McBride,Evangelia Koutelou,Sharon Y.R. Dent

DOI: https://doi.org/10.1158/0008-5472.can-20-2379

IF: 11.2

2020-11-09

Cancer Research

Abstract:Overexpression of the MYC oncoprotein is an initiating step in the formation of several cancers. MYC frequently recruits chromatin-modifying complexes to DNA to amplify the expression of cancer-promoting genes, including those regulating cell cycle, proliferation, and metabolism, yet the roles of specific modifiers in different cancer types are not well defined. Here, we show that GCN5 is an essential coactivator of cell-cycle gene expression driven by MYC overexpression and that deletion of <i>Gcn5</i> delays or abrogates tumorigenesis in the <i>Eμ-Myc</i> mouse model of B-cell lymphoma. Our results demonstrate that <i>Gcn5</i> loss impacts both expression and downstream functions of Myc. SIGNIFICANCE: Our results provide important proof of principle for Gcn5 functions in formation and progression of Myc-driven cancers, suggesting that GCN5 may be a viable target for development of new cancer therapies.

oncology

What problem does this paper attempt to address?

The problem this paper attempts to address is the role of GCN5 in the formation and development of B-cell lymphoma caused by Myc overexpression. Specifically, the researchers observed how the deletion of the GCN5 gene in a mouse model (using the Eµ-Myc mouse model) affects the occurrence and development of Myc-driven B-cell lymphoma. The study found that the absence of GCN5 significantly prolonged the time for Eµ-Myc mice to develop lymphoma and reduced the incidence of lymphoma. Additionally, the loss of GCN5 affected the proliferation capacity of early B-cell subsets induced by Myc, leading to a delay or prevention of lymphoma development.

Through RNA sequencing analysis, the researchers further revealed the mechanism by which GCN5 acts as a co-activator of Myc target genes. The results showed that in B cells with Myc overexpression, GCN5 is involved in regulating the expression of many genes related to the cell cycle, proliferation, and tumor survival. When GCN5 is absent, the expression of these genes is inhibited, thereby affecting the Myc-driven cancer development process. Therefore, GCN5 may be a potential target for developing new therapies against Myc overexpression cancers.